Orbital pseudotumor

Am J Clin Oncol. 2010 Jun;33(3):304-6. doi: 10.1097/COC.0b013e3181a07567.

Abstract

Orbital pseudotumor is a benign condition that accounts for approximately 10% of all orbital mass lesions. Any part of the orbit may be involved. The etiology is unknown. The presentation may be either acute or subacute. Patients may present with a palpable mass, a swollen eyelid, congestion, pain, diminished ocular motility, and/or decreased visual acuity. Approximately, 25% of patients present with bilateral disease. A modest proportion of patients experience resolution of their symptoms without treatment. Biopsy is indicated for those who do not respond to, or relapse after, first-line therapy. Oral corticosteroids are the initial treatment and approximately 80% of patients respond. Roughly half of those who respond to corticosteroids relapse. Second-line therapy consists of either low-dose radiotherapy (20-30 Gy at 2 Gy per fraction), cytotoxic chemotherapy, or immunosuppressive agents. Radiotherapy results in long-term local control rates of 50% or higher. Limited lesions may be successfully resected. A small subset of patients may experience inexorable progression to a fixed, painful, sightless eye and require orbital exenteration.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Biopsy
  • Diagnosis, Differential
  • Diagnostic Imaging / methods
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Orbital Neoplasms / diagnosis
  • Orbital Pseudotumor* / diagnosis
  • Orbital Pseudotumor* / drug therapy
  • Orbital Pseudotumor* / pathology
  • Orbital Pseudotumor* / radiotherapy
  • Orbital Pseudotumor* / surgery
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • Immunosuppressive Agents